EUVIMEDEUVIMED entdecken
Crossref

Oclacitinib ( APOQUEL ®) is a selective Janus kinase 1 inhibitor with efficacy in a canine model of flea allergic dermatitis

Andrea J Gonzales iD, Michelle Aleo, Sean Mahabir, James Messamore, Michael Stegemann

Journal of Veterinary Pharmacology and Therapeutics · 2024

DOI: 10.1111/jvp.13462 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Veterinary Pharmacology and Therapeutics, 2024. Verfasst von Andrea J Gonzales und 4 weiteren Autor:innen. Beteiligte Einrichtung: Veterinary Medicine Research and Development, Zoetis, Kalamazoo, Michigan, USA. Hauptthemen laut MEDLINE: Pyrimidines, Dog Diseases, Sulfonamides. Die Arbeit nennt 17 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oclacitinib is a novel Janus kinase (JAK) inhibitor that potently inhibits JAK1‐dependent cytokines involved in allergy, inflammation, and pruritus (IL‐2, IL‐4, IL‐6, IL‐13, and IL‐31). Oclacitinib (Apoquel®, Zoetis Inc, Parsippany, NJ) is approved for the treatment/control of pruritus associated with allergic dermatitis and treatment/control of clinical manifestations of atopic dermatitis in dogs at least 12 months of age. To evaluate the effectiveness of oclacitinib in dogs with flea allergy dermatitis, the JAK1 selective inhibitor was tested in a placebo‐controlled, masked, single‐dose (0.4 mg/kg) or repeat‐dose (0.4 mg/kg, twice daily for 2 weeks) study. Pruritic behaviors were quantitated by video recording, and erythema and skin lesions were assessed using a 10‐cm visual analog scale (VAS). Results showed that oclacitinib reduced pruritus by 61% as early as 1.5 h after a single oral dose compared to placebo, with an average reduction (compared to placebo) of 85% 1–5 h after dosing (0.4 mg/kg; p < .0001). Oclacitinib also significantly reduced erythema ( p < .0001) and skin lesion ( p < .0005) VAS scores on Day 14 compared to placebo in a repeat dose study. No adverse events were noted during the conduct of these studies. IL‐31 concentrations were elevated in the majority of dogs after flea infestation, suggesting JAK1‐dependent cytokines may drive clinical signs of flea allergy dermatitis. These findings show that oclacitinib, an inhibitor of JAK1‐dependent cytokines involved in allergy and inflammation can rapidly reduce clinical signs associated with flea allergic dermatitis in dogs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyrimidinesDog DiseasesSulfonamidesAnimalsDogsMaleFemaleJanus Kinase 1SiphonapteraPruritusFlea InfestationsDermatitis, AtopicJanus Kinase Inhibitors

Stichwörter der Autor:innen

IL‐31JAK1flea allergy dermatitisinflammationoclacitinibpruritus

Substanzen

oclacitinibPyrimidinesSulfonamidesJanus Kinase 1Janus Kinase Inhibitors

Autor:innen und Institutionen

  • Veterinary Medicine Research and Development, Zoetis, Kalamazoo, Michigan, USA.
  • Veterinary Medicine Research and Development, Zoetis, Zaventem, Belgium.

ORCID-Profile: Andrea J Gonzales

Zitieren

APA

Gonzales, A. J., Aleo, M., Mahabir, S., Messamore, J., & Stegemann, M. (2024). Oclacitinib ( APOQUEL ®) is a selective Janus kinase 1 inhibitor with efficacy in a canine model of flea allergic dermatitis. Journal of Veterinary Pharmacology and Therapeutics. https://doi.org/10.1111/jvp.13462

Vancouver

Gonzales AJ, Aleo M, Mahabir S, Messamore J, Stegemann M. Oclacitinib ( APOQUEL ®) is a selective Janus kinase 1 inhibitor with efficacy in a canine model of flea allergic dermatitis. Journal of Veterinary Pharmacology and Therapeutics. 2024. doi:10.1111/jvp.13462

BibTeX
@article{Gonzales2024,
  author = {Gonzales, Andrea J and Aleo, Michelle and Mahabir, Sean and Messamore, James and Stegemann, Michael},
  title = {Oclacitinib ( APOQUEL ®) is a selective Janus kinase 1 inhibitor with efficacy in a canine model of flea allergic dermatitis},
  journal = {Journal of Veterinary Pharmacology and Therapeutics},
  year = {2024},
  doi = {10.1111/jvp.13462}
}
Kostenlos starten →